Biofrontera Inc. Negotiates Cooperation Changes with Biofrontera AG

An announcement from Biofrontera ( (BFRI) ) is now available.

On June 11, 2025, Biofrontera Inc. announced that it is in negotiations with Biofrontera AG regarding potential changes to their cooperation, including a possible combination of the two companies or adjustments to their license and supply agreement. These negotiations could lead to the transfer of certain rights and obligations from Biofrontera AG to Biofrontera Inc., as well as a reduction in the transfer price for Biofrontera Inc.’s licensed products sold in the U.S. The terms of any agreement are yet to be finalized and are subject to numerous conditions.

The most recent analyst rating on (BFRI) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on Biofrontera stock, see the BFRI Stock Forecast page.

Spark’s Take on BFRI Stock

According to Spark, TipRanks’ AI Analyst, BFRI is a Neutral.

Biofrontera’s stock score reflects financial difficulties, highlighted by negative cash flows and net losses, compounded by regulatory compliance challenges. While there are positive strides in revenue and cost management, these are overshadowed by serious financial and market compliance concerns.

To see Spark’s full report on BFRI stock, click here.

More about Biofrontera

Biofrontera Inc. is a U.S.-based biopharmaceutical company specializing in the treatment of dermatological conditions with a focus on photodynamic therapy (PDT). The company commercializes the drug-device combination Ameluz® with the RhodoLED® lamp series for PDT of actinic keratosis (AK), pre-cancerous skin lesions which may progress to invasive skin cancers. Biofrontera is also conducting clinical trials to extend the use of its products to treat non-melanoma skin cancers and moderate to severe acne.

Average Trading Volume: 142,034

Technical Sentiment Signal: Sell

Current Market Cap: $5.78M

For a thorough assessment of BFRI stock, go to TipRanks’ Stock Analysis page.